Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and myasthenia gravis are now recruiting.
Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and myasthenia gravis are now recruiting.
Academic and corporate partnerships help accelerate our product development, advance our preclinical studies and clinical trial, and expand the reach of our platform. Collaborations with patient advocacy groups enable us to connect with the patient communities and ensure their voices are heard through our product development journey.